Search

Your search keyword '"Roy, Indranil"' showing total 4 results
Start Over Author "Roy, Indranil" Journal indian journal of medical microbiology
4 results on '"Roy, Indranil"'

1. In silico and In vitro Activity of Ceftolozane/Tazobactam Against Pseudomonas aeruginosa Collected Across Indian Hospitals

Author

Pragsam, Agila Kumari, primary, Kumar, D.Thirumal, additional, Priya Doss, C.George, additional, Iyadurai, Ramya, additional, Satyendra, Sowmya, additional, Rodrigues, Camilla, additional, Joshi, Sangeeta, additional, Roy, Indranil, additional, Chaudhuri, Bhaskar Narayan, additional, Chitnis, D.S., additional, Tapan, Dhole, additional, and Veeraraghavan, Balaji, additional

Published
2018
Full Text
View/download PDF

2. Antimicrobial Susceptibility Profiles of Gram-Negative Bacteria Causing Infections Collected Across India during 2014–2016: Study for Monitoring Antimicrobial Resistance Trend Report

Author

Veeraraghavan, Balaji, primary, Jesudason, Mark Ranjan, additional, Jude Prakasah, John Antony, additional, Anandan, Shalini, additional, Sahni, Rani Diana, additional, Pragasam, Agila Kumari, additional, Bakthavatchalam, Yamuna Devi, additional, Selvakumar, Rajesh Joseph, additional, Dhole, T.N., additional, Rodrigues, Camilla, additional, Roy, Indranil, additional, Joshi, Sangeetha, additional, Chaudhuri, Bhaskar Narayan, additional, and Chitnis, D.S., additional

Published
2018
Full Text
View/download PDF

3. Dosing Strategy Based on Prevailing Aminoglycoside Minimum Inhibitory Concentration in India: Evidence and Issues

Author

Veeraraghavan, Balaji, primary, Pragasam, Agila Kumari, additional, Manesh, Abi, additional, Rupali, Priscilla, additional, Iyadurai, Ramya, additional, Rodrigues, Camilla, additional, Joshi, Sangeeta, additional, Roy, Indranil, additional, Chaudhuri, Bhaskar Narayan, additional, Chitnis, D.S., additional, and Tapan, Dhole, additional

Published
2017
Full Text
View/download PDF

4. In silicoand In vitroActivity of Ceftolozane/Tazobactam Against Pseudomonas aeruginosaCollected Across Indian Hospitals

Author

Pragsam, Agila Kumari, Kumar, D.Thirumal, Priya Doss, C.George, Iyadurai, Ramya, Satyendra, Sowmya, Rodrigues, Camilla, Joshi, Sangeeta, Roy, Indranil, Chaudhuri, Bhaskar Narayan, Chitnis, D.S., Tapan, Dhole, and Veeraraghavan, Balaji

Abstract

Ceftolozane/tazobactam is a novel antimicrobial agent with activity against Pseudomonas aeruginosaand other common Gram-negative pathogens. In this study, we determined the antimicrobial susceptibility for a total of 149 clinical isolates of P. aeruginosafor the most commonly used antimicrobials including the new agent ceftolozane/tazobactam (C/T). Broth microdilution was performed to determine the minimum inhibitory concentration against various antimicrobials including C/T. Among the β-lactam/β-lactamase inhibitor, overall susceptibility was 67%, 55% and 51% for C/T, Piperacillin/Tazobactam (P/T) and Cefoperazone/Sulbactam, respectively. The variations in the susceptibility rates were noted among the three different β-lactam/β-lactamase inhibitors. Interestingly, 33% susceptibility was noted for C/T against isolates that were resistant to P/T, indicating the higher activity of C/T. This finding suggests about 33% of the P/T-resistant isolates can still be treated effectively with C/T. C/T could be a better alternative for the treatment of ESBL-producing organism, and thereby usage of higher antimicrobials can be minimised.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results